Innate defense regulator peptide synergizes with CpG ODN for enhanced innate intestinal immune responses in neonate piglets.
The in vivo immunoadjuvant effects of the combination of CpG oligodeoxynucleotide (CpG ODN) and innate defense-regulator peptides (IDRs) have been studied in mice. However, little is known about the efficacy of these molecules in stimulating the innate intestinal immune system in neonatal piglets. In this study, we observed that intranasal (IN) administration of CpG-IDR (peptide HH2 (VQLRIRVAVIRA)) complex significantly increased intestinal mRNA expression of Th1 cytokines, CC chemokines and CXC chemokines when compared to HH2 and CpG ODN alone. Also an obvious cellular infiltration was observed in the intestine of CpG-HH2-treated neonatal piglets, which was associated with increased protection against Enterotoxigenic Escherichia coli (ETEC). Moreover, we showed that pro-inflammatory cytokine TNF-α was inhibited when CpG ODN combined with HH2. This was the first report that deciphered the role played by CpG-HH2 complex in the intestine of neonatal piglets. This work clearly demonstrated that efficiency of the IN route inducing intestinal responses in neonatal piglets might be taken into consideration for further vaccine development against neonatal intestinal diseases.
College of Life Sciences, South China Agricultural University, Guangzhou 510642, China.
Jun
J
Yang
Miaopeng
M
Mao
Shuiqing
S
Zhang
Huazhou
H
Li
Zhenggu
Z
Jiang
Guangjun
G
Cao
Ding
D
Cao
Xingfu
X
Wang
Linghua
L
Zhang
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn / Q000276:immunology; D019742:Chemokines, CC / Q000276:immunology; D019743:Chemokines, CXC / Q000276:immunology; D054307:Enterotoxigenic Escherichia coli / Q000276:immunology; D018928:Immunity, Mucosal / Q000187:drug effects* / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D015847:Interleukin-4 / Q000276:immunology; D007422:Intestines / Q000187:drug effects / Q000276:immunology; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000276:immunology / Q000494:pharmacology*; D010455:Peptides / Q000276:immunology*; D013552:Swine; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D019742:Chemokines, CC; D019743:Chemokines, CXC; D009838:Oligodeoxyribonucleotides; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D015847:Interleukin-4; D007371:Interferon-gamma